A detailed history of Hudson Bay Capital Management LP transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 34,500 shares of DNLI stock, worth $851,805. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,500
Previous 175,000 80.29%
Holding current value
$851,805
Previous $4.06 Million 75.29%
% of portfolio
0.0%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$20.96 - $31.05 $2.94 Million - $4.36 Million
-140,500 Reduced 80.29%
34,500 $1 Million
Q2 2024

Aug 14, 2024

SELL
$14.96 - $23.22 $673,200 - $1.04 Million
-45,000 Reduced 20.45%
175,000 $4.06 Million
Q1 2024

May 15, 2024

BUY
$15.83 - $23.35 $712,350 - $1.05 Million
45,000 Added 25.71%
220,000 $4.51 Million
Q4 2023

Feb 14, 2024

BUY
$16.2 - $23.18 $2.84 Million - $4.06 Million
175,000 New
175,000 $3.76 Million

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.31B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Hudson Bay Capital Management LP Portfolio

Follow Hudson Bay Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.